Taysha Gene Therapies (NASDAQ:TSHA) had its target price increased by Morgan Stanley from $30.00 to $43.00 in a research note published on Monday morning, Benzinga reports. Morgan Stanley currently has an overweight rating on the stock.
Several other research firms have also recently issued reports on TSHA. William Blair started coverage on Taysha Gene Therapies in a research note on Monday, March 1st. They issued an outperform rating and a $46.00 target price on the stock. Chardan Capital raised their target price on Taysha Gene Therapies from $60.00 to $67.50 and gave the stock a buy rating in a research note on Monday. Zacks Investment Research cut Taysha Gene Therapies from a hold rating to a sell rating in a research note on Tuesday, March 9th. Finally, Oppenheimer started coverage on Taysha Gene Therapies in a research note on Monday, January 4th. They issued an outperform rating and a $42.00 target price on the stock. One research analyst has rated the stock with a sell rating and six have given a buy rating to the company’s stock. The stock currently has a consensus rating of Buy and an average target price of $43.92.
Shares of NASDAQ:TSHA opened at $22.82 on Monday. The company’s 50-day moving average is $23.57. Taysha Gene Therapies has a 12-month low of $18.16 and a 12-month high of $33.35.
A number of institutional investors and hedge funds have recently modified their holdings of TSHA. Wells Fargo & Company MN purchased a new position in shares of Taysha Gene Therapies during the fourth quarter valued at approximately $330,000. BlackRock Inc. grew its position in shares of Taysha Gene Therapies by 21.1% during the 4th quarter. BlackRock Inc. now owns 2,229,816 shares of the company’s stock valued at $59,181,000 after acquiring an additional 389,249 shares during the period. Bank of New York Mellon Corp bought a new stake in shares of Taysha Gene Therapies during the 4th quarter valued at $716,000. Citigroup Inc. bought a new stake in shares of Taysha Gene Therapies during the 4th quarter valued at $43,000. Finally, Chartwell Investment Partners LLC bought a new stake in shares of Taysha Gene Therapies during the 4th quarter valued at $497,000. Institutional investors and hedge funds own 42.19% of the company’s stock.
About Taysha Gene Therapies
Taysha Gene Therapies, Inc, a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-101 for the treatment of GM2 gangliosidosis; TSHA-118 for the treatment of CLN1 disease; and TSHA-102 for the treatment of Rett syndrome.
Further Reading: FinTech
Receive News & Ratings for Taysha Gene Therapies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Taysha Gene Therapies and related companies with MarketBeat.com's FREE daily email newsletter.